Study details
Enrolling now
The Impact of AMPA Receptor Blockade on Ketamine's Anti-Suicidal Effects
Yale University
NCT IDNCT05786066ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Target enrollment
30
Study length
about 10 years
Ages
21–65
Locations
1 site in CT
What this study is about
Researchers are testing whether blocking AMPA receptors changes how well ketamine helps with suicidal thoughts. The trial will compare ketamine to a placebo and perampanel, a drug that blocks AMPA receptors.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Ketamine
- 2.Take Perampanel 6 MG
- 3.Take Placebo
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
Oral
How treatment is administered
Treatment Assignment
Randomized & Blinded
You may get a placebo/standard care, and you won't know which.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
ketamine (NMDA receptor antagonist; induces dissociative anesthesia and analgesia), perampanel
Drug routes
oral (Oral Tablet)
Body systems
Psychiatry / Mental Health